Pharmaxo acquired by Icon Group in strategic partnership
Betsy Goodfellow | July 10, 2024 | News story | Business Services | Oncology, Pharmaxo, acquisition, strategic parnership
Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global compounding operator as well as to allow Icon to enter the UK market.
Icon is an ‘operator of integrated cancer care centres throughout Australia, South East Asia and the UK and owner of Slade Health, a specialist compounding operator across Australia and New Zealand’, according to the company’s press release. While Pharmaxo is a ‘leading pharmaceutical specialist manufacturer (Bath ASU) and clinical homecare provider (Pharmaxo Healthcare), based in Corsham, Wiltshire’.
Chris Watt, executive chair of Pharmaxo Group, commented: “For 20 years Bath ASU has been at the heart of the UK compounding sector through shaping the development of chemotherapy dose banding, establishing validated technical training delivered at universities and setting out the standards the NHS now uses to assess the stability of complex biological medicines. We are now at a stage where global scale matters. We believe we can achieve more, and can continue to shape our industry, by joining forces with Icon Group.”
Mark Middleton, Icon Group’s chief executive officer, added: “Welcoming Pharmaxo to Icon Group reflects our ongoing commitment to improving access to world-class healthcare in the UK. Cancer rates continue to rise and there is a significant need to increase manufacturing of cancer drugs to address growing care gaps. Pharmaxo has built a solid foundation for growth. Combined with Icon’s strong 60-year track record in pharmaceuticals and sterile compounding under the Slade Health brand, together we will continue bringing the latest drugs to where people need them in the UK, eliminating unnecessary travel and ensuring timely access to life-saving medications.”
Betsy Goodfellow
Related Content
Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …
Curium Pharma announces acquisition of Monrol
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine …
Enosium Life Science acquires RWEality
Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on …
